TABLE 4.
Univariate analyses to identify independent risk factors of time to recurrence and overall survival in CTC‐positive HCC patients after PSM
| Time to recurrence | Overall survival | |||
|---|---|---|---|---|
| Variable | HR (95% CI) | P‐value | HR (95% CI) | P‐value |
| Gender (Male) | 1.142 (0.603‐2.161) | .684 | 0.822 (0.414‐1.631) | .575 |
| Age (>50 years) | 0.747 (0.479‐1.166) | .199 | 0.618 (0.364‐1.049) | .075 |
| Tumor number (Multiple) | 2.087 (1.336‐3.260) | .001 | 2.540 (1.491‐4.328) | .001 |
| Tumor diameter (>5 cm) | 1.604 (1.027‐2.504) | .038 | 2.057 (1.191‐3.553) | .010 |
| Tumor capsule (None) | 1.345 (0.858‐2.109) | .196 | 1.389 (0.812‐2.374) | .230 |
| Vascular invasion (Yes) | 1.312 (0.827‐2.082) | .248 | 1.241 (0.716‐2.150) | .442 |
| Edmondson stage (III‐IV) | 0.883 (0.562‐1.388) | .590 | 1.161 (0.683‐1.973) | .582 |
| Liver cirrhosis (Yes) | 1.702 (1.073‐2.701) | .024 | 1.517 (0.870‐2.645) | .142 |
| HBsAg (Positive) | 1.586 (0.763‐3.298) | .217 | 1.147 (0.491‐2.681) | .751 |
| AFP (>400 ng/mL) | 2.314 (1.481‐3.615) | <.001 | 3.352 (1.953‐5.753) | <.001 |
| ALT (>50 U/L) | 2.350 (1.473‐3.749) | <.001 | 2.330 (1.356‐4.003) | .002 |
| GGT (>60 U/L) | 1.687 (1.084‐2.625) | .020 | 1.894 (1.114‐3.219) | .018 |
| Adjuvant TACE (Yes) | 0.461 (0.294‐0.723) | .001 | 0.316 (0.178‐0.562) | <.001 |
Bold P‐values indicates statistical significance.
Abbreviations: AFP, alpha‐fetoprotein; ALT, alanine aminotransferase; BCLC, Barcelona Clinic Liver Cancer staging system; CNLC, Liver Cancer Guidelines in China; CTC, circulating tumor cell; GGT, gamma‐glutamyl transpeptidase; HBsAg, Hepatitis B surface antigen; HCC, hepatocellular carcinoma; TACE, transcatheter arterial chemoembolization.